1. Pink Sheet
  2. >>Advanced Technologies
  3. >>AI

AI In Drug Development: Avoid The ‘Flashiness,’ And Simply Ask ‘Does It Fit?’ – US FDA’s ElZarrad

 
• By Kate Rawson

The Center for Drug Evaluation and Research’s medical policy chief says artificial intelligence can aid patient recruitment and increase trial diversity, but warned of “unique” potential pitfalls for sponsors.

artificial intelligence
ElZarrad said the FDA may have to think of new approaches for AI transparency. • Source: Shutterstock

Drug developers should avoid falling for the “flashiness” of digital health technologies powered by artificial intelligence, as well as ensure they make sense and do not increase the complexity of clinical development, Khair ElZarrad, director of the US Food and Drug Administration Center for Drug Evaluation and Research’s Office of Medical Policy, said.

Key Takeaways

  • Sponsors may be attracted to using AI, but first must ask whether the tool fits the context of the clinical trial, Khair ElZarrad said.

  • AI can help predict potential trial drop-outs, which can be used to improve retention, ElZarrad said

“We call them this new tool,” ElZarrad said during a recent “Q&A with the FDA” podcast

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from AI

US HHS Deputy Nominee Talks AI, Not FDA, In Confirmation Hearing

 
• By Ramsey Baghdadi

Silicon Valley investor Jim O’Neill’s Senate confirmation hearings showcased the unique background of someone with government and tech experience and avoided discussions of his past statements about lowering the bar for regulatory approval.

Canada’s HTA Agency Reveals How To Submit AI-Driven Evidence

 
• By Neena Brizmohun

Recognizing that the evidence it receives in applications for health technology assessments will increasingly be informed by artificial intelligence, the CDA-AMC has clarified its expectations for companies that use AI methods in the generation and/or reporting of evidence.

AI Could Be Used ‘In The Deliberation’ Of HTA Reviews In England, Says NICE

 
• By Eliza Slawther

England’s health technology assessment institute, NICE, is looking to “reimagine” its evaluation process with the help of AI, rather than just using this technology to speed up its existing processes.

EMA’s Newly Qualified AI Tool To Boost MASH Market Dynamics

 
• By Neena Brizmohun

The European Medicines Agency’s qualification of the AIM-NASH tool is said to signify a major advancement for clinical trials for metabolic dysfunction-associated steatohepatitis. The market size for MASH treatments is expected to grow substantially in the coming years.

More from Advanced Technologies